Skip to content

Teclistamab

ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS

Also known as: BCMAxCD3, JNJ-64007957, teclistamab-cqyv, tecvayli

EMA approvedFDA approvedOrphan designationATC L01FX24

Data last refreshed: (DrugCentral release 2024-11-01)

Key facts

Teclistamab is a drug catalogued in DrugCentral. It was first approved by the EMA in 2022. DrugCentral lists 2 molecular targets, including TNFRSF17 and CD3E|CD3G|CD3D. Recorded indications include Relapsed or refractory multiple myeloma.

  • Molecular targets: TNFRSF17 and CD3E|CD3G|CD3D (2 listed in DrugCentral).
  • Indications: Relapsed or refractory multiple myeloma.
  • ATC code: L01FX24 (Other monoclonal antibodies and antibody drug conjugates).

Indications & contraindications

Drug–disease relationships curated by DrugCentral (OMOP / SNOMED concepts).

Indications (1)

  • Relapsed or refractory multiple myeloma

Mechanism & targets

Molecular targets (2)

TargetGeneActionActivity
Tumor necrosis factor receptor superfamily member 17TNFRSF17otherKd 9.74
T-cell surface glycoprotein CD3CD3E|CD3G|CD3DotherKd 7.55

Regulatory approvals (2)

DateAgencyMarketed asApplicantOrphan
2022-10-25FDA—JANSSEN BIOTECHYes
2022-08-23EMA—JANSSEN-CILAG INTERNATIONAL N.V.

ATC classification

ATC codeTherapeutic hierarchy
L01FX24ANTINEOPLASTIC AND IMMUNOMODULATING AGENTS › ANTINEOPLASTIC AGENTS › MONOCLONAL ANTIBODIES AND ANTIBODY DRUG CONJUGATES › Other monoclonal antibodies and antibody drug conjugates

Pharmacogenomics

Drug-label and guideline annotations from PharmGKB and CPIC.

  • EMA label
  • FDA label
  • HCSC label

Reported adverse-event signals

Strongest FDA FAERS disproportionality signals (log-likelihood ratio). A signal is a statistical association in spontaneous reports, not proof that the drug causes the event.

MedDRA termLLR
Cytokine release syndrome3088.9
Immune effector cell-associated neurotoxicity syndrome1395.4
COVID-19229.4
Hypogammaglobulinaemia221.9
Infection163.2
IVth nerve paralysis152.9
IgA nephropathy139.8
Neutropenia138.7
Neurotoxicity95.9
Progressive multifocal leukoencephalopathy92.4
COVID-19 pneumonia89.7
Pneumonia89.7

Chemical structure

Molecular formula—
Molecular weight—
CAS number2119595-80-9
InChIKey—
PubChem CID—

Frequently asked questions

Answers are generated from the structured data on this page, not written by hand.

What is Teclistamab used for?

DrugCentral lists the following indications for Teclistamab: Relapsed or refractory multiple myeloma.

How does Teclistamab work?

Its molecular targets in DrugCentral include TNFRSF17 and CD3E|CD3G|CD3D.

When was Teclistamab first approved?

Teclistamab was first approved by the EMA in 2022.

Browse: all drugs starting with T · drug guides by category · protein targets A–Z.

Sources

How this page is built: methodology · editorial policy & corrections.

For research and educational use only — not medical advice. This page is compiled automatically from public databases. It is not written or reviewed by a clinician. Do not start, stop or change any treatment based on it; consult a qualified healthcare professional. Spotted an error? See our corrections policy or email hello@molforge.ai.

Quick facts

Status—
First approval2022-08-23
AgencyEMA
Targets2
Indications1
Formula—
DrugCentral ID5706
Interactive profile